INMED PHARMACEUTICALS INC (INM) Stock Price, Quote, News and Overview
NASDAQ:INM - Nasdaq - CA4576377002 - Common Stock
INM Quote and Key Statistics
INMED PHARMACEUTICALS INC
NASDAQ:INM (1/21/2025, 8:07:43 PM)
Premarket: 4.24 -0.81 (-16.04%)5.05
+0.1 (+2.02%)
INM Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.14% | ||
| ROE | -81.19% | ||
| Debt/Equity | 0 |
INM Performance and Technical Analysis
INM Ownership and Analysts
INM Latest News and Analysis
Get insights into the top gainers and losers of Tuesday's after-hours session.
Get insights into the top gainers and losers of Tuesday's after-hours session.
Which stocks are moving before the opening bell on Tuesday?
Stay updated with the stocks that are on the move in Tuesday's pre-market session.
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise
The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform.
Why InMed Pharmaceuticals (INM) Stock Is Skyrocketing
InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.
About INM
Company Profile
InMed Pharmaceuticals Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. InMed Pharmaceuticals Inc. is a pharmaceutical company. The company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Company Info
INMED PHARMACEUTICALS INC
1445-885 West Georgia St.
Vancouver BRITISH COLUMBIA V6C1B4 CA
CEO: Eric Adams
Employees: 13
Company Website: https://www.inmedpharma.com/
Investor Relations: http://www.inmedpharma.com/s/stock-info.asp
Phone: 16046697207
INM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.43 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |